|
|
||||||||
142, in TNF-
-Activated Microglia1,2


* Laboratory of Molecular Immunoregulation and
Laboratory of Experimental Immunology, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702; and
Basic Research Program, SAIC-Frederick, Frederick, MD 21702
Microglia are phagocytic cells in the CNS and actively participate in proinflammatory responses in neurodegenerative diseases. We have previously shown that TNF-
up-regulated the expression of formyl peptide receptor 2 (mFPR2) in mouse microglial cells, resulting in increased chemotactic responses of such cells to mFPR2 agonists, including amyloid
142 (A
42), a critical pathogenic agent in Alzheimers disease. In the present study, we found that IL-4, a Th2-type cytokine, markedly inhibited TNF-
-induced expression of mFPR2 in microglial cells by attenuating activation of ERK and p38 MAPK as well as NF-
B. The effect of IL-4 was not dependent on Stat6 but rather required the protein phosphatase 2A (PP2A) as demonstrated by the capacity of PP2A small interfering RNA to reverse the effect of IL-4 in TNF-
-activated microglia. Since both IL-4 and TNF-
are produced in the CNS under pathophysiological conditions, our results suggest that IL-4 may play an important role in the maintenance of CNS homeostasis by limiting microglial activation by proinflammatory stimulants.
This article has been cited by other articles:
![]() |
S. Jimenez, D. Baglietto-Vargas, C. Caballero, I. Moreno-Gonzalez, M. Torres, R. Sanchez-Varo, D. Ruano, M. Vizuete, A. Gutierrez, and J. Vitorica Inflammatory Response in the Hippocampus of PS1M146L/APP751SL Mouse Model of Alzheimer's Disease: Age-Dependent Switch in the Microglial Phenotype from Alternative to Classic J. Neurosci., November 5, 2008; 28(45): 11650 - 11661. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Afkhami-Goli, F. Noorbakhsh, A. J. Keller, N. Vergnolle, D. Westaway, J. H. Jhamandas, P. Andrade-Gordon, M. D. Hollenberg, H. Arab, R. H. Dyck, et al. Proteinase-Activated Receptor-2 Exerts Protective and Pathogenic Cell Type-Specific Effects in Alzheimer's Disease J. Immunol., October 15, 2007; 179(8): 5493 - 5503. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |